Article

Sponsored Content

Lonza Pharma & Biotech

Author(s):

Lonza Pharma & Biotech

Due to the intrinsic enteric properties of Capsugel® Vcaps® Enteric, no coating step is needed. It means that this capsule is a ready-to-use solution that can help you in obtaining significant cost and time savings during pharmaceutical development or compounding.

Capsugel® Vcaps® Enteric Capsule is a fully compliant capsule technology that simplifies drug enteric delivery implementation from early-stage development to commercial manufacturing. The pharmaceutical grades of cellulosic derivatives used in Capsugel® Vcaps® Enteric capsules are approved and have extensive market precedence for use in providing enteric protection. They have been evaluated in-vitro and in-vivo across a number of compounds, which has proven full compliance with relevant European, Japanese and US Pharmacopeia monographs.

 

Capsugel® Vcaps® Enteric capsules can be utilized to greatly simplify and accelerate prototype development and rapid in-vivo testing of products requiring targeted delivery to the upper GI tract:

  • Eliminate coating system preparation and application steps


  • Rapid screening and optimization of enteric performance


  • Remove dependency of enteric functionality with process variability


  • Obviate need for process development of the enteric coating step, process scale-up and validation

Product Description

  • Two-piece hard capsule


  • Manufactured with pharmaceutical-grade cellulosic derivatives (HPMCAS, HPMC)

 

Contact Details:

Company name: Lonza Pharma & Biotech
Website: www.capsugel.com/biopharmaceutical-products/vcaps-enteric-capsules
E-mail: solutions.emea@lonza.com

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content
medicine factory scientist worker work in Laboratory Plants Process. medical doctor working research in pharmaceutical industry. | Image Credit: ©Quality Stock Arts – stock.adobe.com
July 25th 2025

Interfering with Interventions in Aseptic Processing

James Agalloco
Addressing human interventions to reduce their impact on contamination requires addressing broader considerations than limiting operator activities. Equipment, automation, procedural and component changes can be utilized to make the aseptic activities safer. This article offers suggestions for reducing the adverse impact of intervention throughout the aseptic process.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Oil painting of maze with figure finding way through. Perseverance, problem-solving. Birds fly above labyrinth at sunset. Concept of challenges, resilience, journey, overcoming obstacles in business | Image Credit © Vadym - stock.adobe.com
July 25th 2025

CMC and Analytical Gaps in CRLs: Why They Persist Despite FDA Guidance and How You Can Position Yourself for Success

Christopher Cole
Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and analytical issues despite early regulatory guidance. Review key risk points in analytical and tech transfer to better ensure commercial readiness.
Site Logo
March 28th 2025

Transformations in Drug Development for Cell and Gene Therapies

PPD Thermo Fisher Scientific
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Sand running through the bulbs of an hourglass | Image Credit: © BillionPhotos.com - stock.adobe.com
July 24th 2025

Customizable Relationships Enhance Speed to Market

Patrick Lavery
While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Mercury. Element 80 of the periodic table of chemical elements. | Image Credit: © N. Elkha - stock.adobe.com
July 24th 2025

Opposing Reactions as RFK Jr. Removes Thimerosal from Flu Vaccines

Patrick Lavery
Following an overhaul at ACIP, the HHS secretary took the advice of the committee’s new members, saying he was acting on guidance that dated back to 1999.